Finance
FDA tells uniQure early trial data insufficient for brain disorder therapy filing
Published by Global Banking & Finance Review®
Posted on March 2, 2026
2 min readLast updated: March 2, 2026
Quick Summary
The FDA has informed uniQure that its Phase I/II gene therapy data for Huntington’s disease (AMT‑130) are not sufficient to support a marketing application, sending the company’s shares sharply lower.
UniQure slides after FDA says trial data insufficient for brain disorder therapy filing
FDA Decision Impacts UniQure's Huntington's Disease Gene Therapy
Background on UniQure's Gene Therapy and Huntington's Disease
March 2 (Reuters) - UniQure said on Monday the U.S. drug regulator had informed that data from an early- to mid-stage trial of its brain disorder gene therapy would not support its approval application, sending its shares down 40% in premarket trading.
The Dutch company was testing its gene therapy AMT-130 in patients with Huntington's disease — a fatal, inherited neurodegenerative disorder causing progressive breakdown of nerve cells in the brain. Currently, there are no approved treatments to slow the disease's progression.
FDA's Recommendation and Study Results
UniQure said the U.S. Food and Drug Administration recommended it to run a new study that randomly assigns patients to get either the gene therapy, or a sham surgery.
In September, data from the early- to mid-stage study showed a 75% reduction in disease progression in a three-year analysis, based on a widely used clinical scale.
Analyst and Company Reactions
The regulator "seems to be devoid of disease state expertise, especially given its leadership biases against cell and gene therapy," said Guggenheim analyst Debjit Chattopadhyay.
"FDA leadership speaks eloquently on regulatory flexibility... actions reflect a premeditated bias. Path forward for AMT-130 remains murky to say the least," Chattopadhyay said.
Next Steps for UniQure
UniQure had initially planned to submit a marketing application to the FDA in early 2026, with hopes of launching the therapy later in the year following potential approval.
"Totality and durability of our data warrant continued substantive dialogue regarding how the FDA's stated commitment to regulatory flexibility may be appropriately applied in this setting," said CEO Matt Kapusta.
The company said it would continue engaging with the FDA regarding late-stage development considerations and plans to request a meeting in the second quarter of 2026 to further discuss potential study design approaches.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
Key Takeaways
- •The FDA concluded that uniQure's early‑ to mid‑stage trial data—compared to an external control—are inadequate as primary evidence for approval.
- •UniQure plans to run a new randomized trial, comparing AMT‑130 to sham surgery, to meet regulatory expectations.
- •Despite initial regulatory optimism—including Breakthrough Therapy and RMAT designations—this setback significantly raises uncertainty around AMT‑130’s approval timeline.
Frequently Asked Questions about FDA tells uniQure early trial data insufficient for brain disorder therapy filing
1What did the FDA say about uniQure's gene therapy trial data?
The FDA informed uniQure that early- to mid-stage trial data was insufficient to support a marketing application for its gene therapy for Huntington's disease.
2How did uniQure's stock react to the FDA news?
UniQure's shares slumped nearly 44% in premarket trading after the FDA's feedback.
3What recommendation did the FDA make to uniQure?
The FDA recommended that uniQure conduct a new study randomly assigning patients to receive the gene therapy or a sham surgery.
4Why can't uniQure's current data support approval?
The results from existing studies, when compared to an external control, cannot serve as primary evidence of effectiveness required by the FDA.
5What is Huntington's disease?
Huntington's disease is a fatal, inherited neurodegenerative disorder causing progressive breakdown of nerve cells in the brain.
